Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin

American Journal of Cardiology

Volumn 84, Issue 6, 1999, Pages 639-643

  Dangas, George ^a   Smith, Donald A ^b   Badimon, Juan J ^b   Unger, Allen H ^b   Shao, John H ^b   Meraj, Perwaiz ^b   Cohen, Adam M ^b   Levine, Daniel ^b   Fallon, John T ^b   Ambrose, John A ^b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7A; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; FIBRINOPEPTIDE A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; PROTHROMBIN; THROMBIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; THROMBOGENESIS; THROMBOGENICITY;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; FEMALE; FIBRINOGEN; FIBRINOLYSIS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION; PRAVASTATIN; PROTHROMBIN; SEX FACTORS; THROMBIN; THROMBOPHILIA; TRIGLYCERIDES;

EID: 0033568438     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00408-7     Document Type: Article

References (21)

1. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
2. Randomized trial of cholesterol lowering in 4444 patients with coronary disease The Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
3. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langerdorfer A., Stein E.A., Kruyer W., Gotto A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS/TexCAPS . JAMA. 279:1998;1615-1622.
4. Lewis S.J., Sacks F.M., Mitchell J.S., East C., Glasser S., Kell S., Letterer R., Limacher M., Moye L.A., Rouleau J.L., Pfeffer M.A., Braunwald E. Effect of pravastatin on cardiovascular events in women after myocardial infarction:the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol. 32:1998;140-146.
5. Gebara O.C., Mittleman M.A., Sutherland P., Lipinska I., Matheney T., Xu P., Welty F.K., Wilson P.W., Levy D., Muller J.E., et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation. 91:1995;1952-1958.
6. Heinemann L.A., Lewis M.A., Spitzer W.O., Thorogood M., Guggenmoos-Holzmann I, Bruppacher R. Thromboembolic stroke in young women. A European case-control study on oral contraceptives. Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception. 57:1998;29-37.
7. Giri S., Thompson P.D., Taxel P., Contois J.H., Otvos J., Allen R., Ens G., Wu A.H., Waters D.D. Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men. Atherosclerosis. 137:1998;359-366.
8. Dangas G., Badimon J.J., Smith D.A., Unger A.H., Levine D., Shao J.H., Meraj P., Fier C., Fallon J.T., Ambrose J.A. Pravastatin therapy in hyperlipidemia:effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol. 33:1999;5:1294-5:1304.
9. Lacoste L., Lam J.Y.T., Hung J., Letchacovski G., Solymoss C.B., Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 92:1995;3172-3177.
10. Rauch U., Badimon J.J., Vorchheimer D.A., et al. Lipid lowering therapy reduces blood thrombogenicity in hypercholesterolemic patients effect of simvastatin . J Am Coll Cardiol. 31:(suppl A):1998;194A.
11. Tsuda Y., Satoh K., Kitadi M. Effects of prevastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis. 122:1996;225-233.
12. Lacoste L., Lam J.Y.T. Comparative effect of pravastatin and simvastatin on platelet thrombus formation in hypercholesterolemic coronary patients. J Am Coll Cardiol. 27:(suppl A):1996;413A.
13. Rose G.A. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull Wld Health Org. 27:1962;645-658.
14. Badimon L., Turitto V., Rosemark J.A., Badimon J.J., Fuster V. Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene . J Lab Clin Med. 110:1987;706-718.
15. Morrissey J.H., Macik B.G., Neuenschwander P.F., Comp P.C. Quantification of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 81:1993;734-744.
16. Dangas G., Badimon J.J., Coller B.S., Fallon J.T., Sharma S.K., Hayes R.M., Meraj P., Ambrose J.A., Marmur J.D. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition under dynamic flow conditions. Implications for a potential anticoagulant effect of abciximab. Arterioscl Thromb Vasc Biol. 18:1998;1342-1349.
17. Vanderkerchove Y., Baele G., dePuydt H., Weyne A., Clement D. Plasma tissue plasminogen activator levels in patients with coronary heart disease. Thromb Res. 50:1988;449-453.
18. Ridker P.M., Vaughn D.E., Stampfer M.J. Baseline fibrinolytic state and the risk of future venous thrombosis a prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor . Circulation. 85:1992;1822-1827.
19. Egashira K., Hirooka Y., Inou T., Kai H., Sugimachi M., Suzuki S., Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent, coronary vasomotion in patients with hypercholesterolemia. Circulation. 89:1994;2519-2524.
20. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., Ganz P. The effect of cholesterol-lowering, and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 332:1995;488-493.
21. Wierzbicki A.S., Lumb P.J., Semra Y.K., Crook M.A. Effect of atorvastatin on plasma fibrrinogen. Lancet. 351:1998;569-570.